NCT04545762
- Conditions
- Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +36 more
- Locations
-
- University of California, San Francisco San Francisco, California, United States
Clinical trial condition
Primary Mediastinal Large B Cell Lymphoma
Explore clinical trials studying Primary Mediastinal Large B Cell Lymphoma. Study availability and eligibility vary by location and protocol.
15 public trials
5 recruiting studies
Primary Mediastinal Large B Cell Lymphoma trial results
NCT05934448
- Conditions
- Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Recurrent, +3 more
- Locations
-
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center New York, United States
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +66 more
- Locations
-
- Banner Health - MD Anderson Cancer Center Gilbert, Arizona, United States
- Christiana Care Hospital - Helen F Graham Cancer Center Newark, Delaware, United States
- Napa Research Pompano Beach, Florida, United States
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
NCT05326243
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3A, Follicular Lymphoma Grade 3B, +13 more
- Locations
-
- National Taiwan University Hospital Taipei, Taiwan
- Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Taiwan
- Chi Mei Medical Center Tainan, Taiwan
- Taipei Medical University - Taipei Medical University Hospital Taipei, Taiwan
NCT05377307
- Conditions
- Dendritic Cell Sarcoma, Interdigitating, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3A, +16 more
- Locations
-
- Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung, Taiwan
- National Taiwan University Hospital Taipei, Taiwan
- Taipei Veterans General Hospital Taipei, Taiwan
- Chi Mei Medical Center Tainan, Taiwan
Not Yet Recruiting
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
NCT07225439
- Conditions
- B-cell Non Hodgkin Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +30 more
- Locations
-
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center Cleveland, Ohio, United States
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute Cleveland, Ohio, United States
NCT05653271
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma, DLBCL, +23 more
- Locations
-
- AdventHealth Orlando Orlando, Florida, United States
- Emory University Atlanta, Georgia, United States
- Indiana University Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
- Norton Cancer Institute Louisville, Kentucky, United States
NCT04488354
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +47 more
- Locations
-
- City of Hope National Medical Center Duarte, California, United States
- University of California at San Diego San Diego, California, United States
- University of Chicago Chicago, Illinois, United States
- Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States
NCT04067414
- Conditions
- Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +12 more
- Locations
-
- Institute of Hematology & Blood Diseases Hospital Tianjin, China
NCT01516567
- Conditions
- Primary Mediastinal Large B Cell Lymphoma
- Locations
-
- University Hospitals Leuven Leuven, Belgium
- Children Oncology Group Operations centres Monrovia, Canada
- Gustave Roussy Villejuif, France
- 2nd Dept. of Pediatrics Semmelweis Univ. Budapest, Hungary